Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Omega-3 fatty acids—particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from fish oil—have been explored as adjunctive therapy for Inflammatory Bowel Disorders (IBD), including Crohn’s disease and ulcerative colitis. Their use is based on the anti-inflammatory properties of omega-3 fats, which modulate the production of pro-inflammatory eicosanoids and cytokines that play a role in IBD pathogenesis. Preclinical studies and some small clinical trials have shown that omega-3 supplementation can reduce disease activity or prolong remission in IBD patients. However, large, well-controlled clinical trials and meta-analyses have yielded mixed results. For example, a 2014 Cochrane review concluded that omega-3 fatty acids are probably ineffective for maintaining remission in Crohn's disease, and evidence for ulcerative colitis is similarly inconclusive. Some patients may experience mild benefits, but the overall effect size is small and not consistently reproducible. Most current guidelines do not recommend routine omega-3 supplementation as primary therapy for IBD, but it is sometimes considered as adjunctive therapy, especially in patients seeking dietary approaches. In summary, while there is a scientific rationale and some supporting evidence, the quality and consistency of data are limited, resulting in a modest evidence rating.

More about omega-3 fatty acids
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by omega-3 fatty acids

Products containing omega-3 fatty acids

Nature's Sunshine Flax Seed Oil (With Lignans)